...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Reiterating from ClinicalTrials.gov
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Primary Outcome Measures  :
  1. Time to first occurrence of adjudication-confirmed narrowly defined MACE [ Time Frame: 120 weeks ]
    Narrowly defined MACE(major adverse cardiac event) is defined as a single composite endpoint of CV death or non-fatal MI or stroke
Secondary Outcome Measures  :
  1. Time to first occurrence of adjudication-confirmed broadly defined MACE [ Time Frame: 120 weeks ]
    Broadly defined MACE (major adverse cardiac event) is the occurrence of any of the following: CV death, non-fatal MI, hospitalization for CVD events, or stroke
  2. Group difference in all-cause mortality [ Time Frame: 120 weeks ]
  3. Percent change in apoA-I concentration over time within and between treatment groups [ Time Frame: 120 weeks ]
  4. Percent change in apoB concentration over time within and between treatment groups [ Time Frame: 120 weeks ]
  5. Percent change in LDL-C concentration over time within and between treatment groups [ Time Frame: 120 weeks ]
  6. Percent change in HDL-C concentration over time within and between treatment groups [ Time Frame: 120 weeks ]
  7. Percent change in TG concentration over time within and between treatment groups [ Time Frame: 120 weeks ]
  8. Change in HbA1c over time within and between treatment groups [ Time Frame: 120 weeks ]
  9. Change in fasting glucose over time within and between treatment groups [ Time Frame: 120 weeks ]
  10. Change in fasting insulin over time within and between treatment groups [ Time Frame: 120 weeks ]
  11. Change in alkaline phosphatase (ALP) over time within and between treatment groups [ Time Frame: 120 weeks ]
    including isoforms for whole population and quartiles of ALP baseline concentration
  12. Change in kidney function in population [ Time Frame: 120 weeks ]
    baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.7m2
  13. Incidence of AEs and Serious AEs within and between treatment groups [ Time Frame: 120 weeks ]
Other Outcome Measures:
  1. Percent change in hsCRP within and between treatment groups [ Time Frame: 120 weeks ]
  2. Percent change in fibrinogen within and between treatment groups [ Time Frame: 120 weeks ]
  3. Transcription (messenger RNA [mRNA]) change in whole blood [ Time Frame: 6 weeks ]
  4. Health Related Quality of Life (HRQOL) as measured using the EQ-5D-5L [ Time Frame: 122 weeks ]
9 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply